Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Discussion of a phase 3 clinical trial in progress, investigating the efficacy of the triple combination of ibrutinib plus venetoclax and obinutuzumab with response-dependent discontinuation.
Join CLL Society and Dr. Adrian Wiestner with National Institutes of Health (NIH) and clinical trials nurse Kaitlin Kennard with UPENN to learn more about clinical trials, who should consider participating, what questions you should ask, and your rights. Christina Rodriguez Fuller will share her experience in a clinical trial as part of her frontline treatment for CLL.
Is a Clinical Trial Right for You? Monday, May 16, 2022 11 AM PT, 12 PM MT, 1 PM CT, 2 PM ET (Duration 75 minutes) Register Now! Description: Clinical trials
CLL / SLL Opening Trials & Status Updates Opening Trials & Status Updates Clinical Trials can greatly broaden the potential for effective treatment for your CLL. When CLL / SLL trials
Clinical Trial Basics In this section you can learn the basics about clinical trials, including FAQs, trial phases, how to navigate Clinicaltrials.gov, and much more… Clinical Trial Basics In this section you
The combination of umbralisib plus ublituximab, often abbreviated to U2, has promising activity in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL) as shown in this ASH 2021 abstract:
Ask the Lab Scientist Question: Do you know of any ongoing clinical trial that is studying the seronegative response of COVID antibodies after the vaccination? I have read that it is
Dr. Brian Koffman spoke with Dr. Kerry Rogers, assistant professor and hematologist in the Division of Hematology at the Ohio State University, about an upcoming phase I clinical trial of VIP152, a new cyclin-dependent kinase 9 (CDK9) inhibitor for patients with double refractory CLL or Richter syndrome.
Clinical Trial Phases, the Drug Approval Process, and Measuring Responses In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are
One click to our most popular content.
